MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2824-2830

  Wang, Siliang ^a   Chen, Xiaodong ^a   Tang, Meiyue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

JAK2; MicroRNA; Pancreatic cancer; STAT3

Indexed keywords

JANUS KINASE 2; MESSENGER RNA; MICRORNA; MICRORNA 216A; STAT3 PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; MIRN216 MICRORNA, HUMAN; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JAK2 GENE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 GENE; SURVIVIN GENE; TUMOR XENOGRAFT; WESTERN BLOTTING; X LINKED INHIBITOR OF APOPTOSIS GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MICRORNAS; PANCREATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914677243     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3478     Document Type: Article

References (50)

1. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
2. Kleeff J, Michalski CW, Friess H and Büchler MW: Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur J Surg Oncol 33: 817-823, 2007.
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma e6201: a trial of the eastern Cooperative oncology Group. J Clin Oncol 27: 3778-3785, 2009.
5. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006.
6. Conroy T, Desseigne F, Ychou M, et al: FolFIRINoX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
7. Schneider G and Schmid RM: Genetic alterations in pancreatic carcinoma. Mol Cancer 2: e15, 2003.
8. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adeno-carcinoma. Genes Dev 20: 1218-1249, 2006.
9. Chiu J and Yau T: Metastatic pancreatic cancer: are we making progress in treatment? Gastroenterol Res Pract 2012: e898931, 2012.
10. Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187, 2012.
11. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
12. Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11: 228-234, 2009.
13. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
14. Drakaki A and Iliopoulos D: MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J 36: 200-208, 2013.
15. Hou B, Jian Z, Chen S, et al: Expression of miR-216a in pancreatic cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao 32: 1628-1631, 2012 (In Chinese).
16. Link A, Becker V, Goel A, Wex T and Malfertheiner P: Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PloS One 7: e42933, 2012.
17. Yu J, Li A, Hong SM, Hruban RH and Goggins M: MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18: 981-992, 2012.
18. Scholz A, Heinze S, Detjen KM, et al: Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905, 2003.
19. Zhong Z, Wen Z and Darnell Je Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
20. Shuai K, Horvath CM, Huang LH, et al: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76: 821-828, 1994.
21. Chan KS, Sano S, Kiguchi K, et al: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114: 720-728, 2004.
22. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
23. Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251: 199-210, 2007.
24. Kumar C, Purandare AV, Lee FY and Lorenzi MV: Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene 28: 2305-2313, 2009.
25. -ΔΔCT met hod. Methods 25: 402-408, 2001.
26. Ali S, Banerjee S, Logna F, et al: Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol 227: 3373-3380, 2012.
27. Jeyapalan Z, Deng Z, Shatseva T, et al: Expression of CD443'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 39: 3026-3041, 2011.
28. Kato M, Putta S, Wang M, et al: TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTeN. Nat Cell Biol 11: 881-889, 2009.
29. Kato M, Wang L, Putta S, et al: Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells. J Biol Chem 285: 34004-34015, 2010.
30. Chen PJ, Yeh SH, Liu WH, et al: Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology 56: 632-643, 2012.
31. Usborne AL, Smith AT, Engle SK, et al: Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis models. Toxicol Pathol 42: 195-203, 2014.
32. Blenkiron C, Askelund KJ, Shanbhag ST, et al: MicroRNAs in mesenteric lymph and plasma during acute pancreatitis. Ann Surg: Feb 6, 2014 (epub ahead of print).
33. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
34. Gabler K, Behrmann I and Haan C: JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myelopro-liferative neoplasms. JAKSTAT 2: e25025, 2013.
35. Miao L, Liu K, Xie M, Xing Y and Xi T: miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. Cancer Immunol Immunother 63: 699-711, 2014.
36. Corcoran RB, Contino G, Deshpande V, et al: STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71: 5020-5029, 2011.
37. Miyatsuka T, Kaneto H, Shiraiwa T, et al: Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev 20: 1435-1440, 2006.
38. Lee JK, Edderkaoui M, Truong P, et al: NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephos-phorylation by tyrosine phosphatases. Gastroenterology 133: 1637-1648, 2007.
39. Palagani V, Bozko P, El Khatib M, et al: Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogenesis 35: 859-866, 2014.
40. Butturini E, Carcereri de Prati A, Chiavegato G, et al: Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med 65: 1322-1330, 2013.
41. Kim JK, Kim JY, Kim HJ, et al: Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PloS One 8: e80391, 2013.
42. Ørom UA, Kauppinen S and Lund AH: lNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372: 137-141, 2006.
43. Lahdaoui F, Delpu Y, Vincent A, et al: miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene 0: 1-9, 2014.
44. Zhao G, Wang B, Liu Y, et al: miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 12: 2569-2580, 2013.
45. Miao L, Xiong X, Lin Y, et al: miR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett 7: 658-662, 2014.
46. Huang F, Tang J, Zhuang X, et al: MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PloS One 9: e87897, 2014.
47. Patel K, Kollory A, Takashima A, et al: MicroRNA let-7 down-regulates STAT3 phosphorylation in pancreatic cancer cells by increasing SoCS3 expression. Cancer Lett 347: 54-64, 2014.
48. Song S, Zhou J, He S, et al: Expression levels of microRNA-375 in pancreatic cancer. Biomed Rep 1: 393-398, 2013.
49. Menghini R, Casagrande V, Marino A, et al: MiR-216a: a link between endothelial dysfunction and autophagy. Cell Death Dis 5: e1029, 2014.
50. Yang S, Wang X, Contino G, et al: Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729, 2011.